Why the study?
The study was conducted to demonstrate the safety and efficacy of the next-generation balloon-expandable Myval transcatheter heart valve in intermediate- or high-risk patients with severe symptomatic native aortic stenosis.
Does the Myval transcatheter heart valve improve clinical and echocardiographic outcomes safely in intermediate- or high-risk patients with severe symptomatic native aortic stenosis?
Does the Myval transcatheter heart valve improve clinical and echocardiographic outcomes safely in intermediate- or high-risk patients with severe symptomatic native aortic stenosis?
The first-in-human MyVal-1 study demonstrated that the Myval transcatheter heart valve is safe and effective at 12 months for severe symptomatic aortic stenosis, notably with a 0% new permanent pacemaker rate.
AIMS: The aim of this study was to demonstrate the safety and efficacy of the next-generation balloon-expandable Myval transcatheter heart valve (THV) in an intermediate- or high-risk patient population with severe symptomatic native aortic stenosis. METHODS AND RESULTS: MyVal-1 was a first-in-human, prospective, multicentre, single-arm, open-label study. Between June 2017 and February 2018, a total of 30 patients were enrolled at 14 sites across India. Mean age was 75.5±6.7 years; 43.3% had coronary artery disease. The mean Society of Thoracic Surgeons score was 6.4±1.8% and 100% of the patients were in New York Heart Association (NYHA) functional Class II/III/IV pre-procedure. The six-minute walk test and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores were recorded. After successful implantation of the Myval THV, 96.6% and 100% were in NYHA functional Class I/II at 30-day and 12-month follow-up, respectively. Outcomes of the six-minute walk test (148.0±87.4 vs 336.0±202.9 m) and KCCQ score (36.6±11.0 vs 65.9±11.4) improved from baseline to 12-month follow-up. The effective orifice area (0.6±0.2 vs 1.8±0.3 cm2, p<0.0001), mean aortic valve gradient (47.4±8.8 vs 12.0±3.3 mmHg, p<0.0001), peak aortic valve gradient (71.7±13.0 vs 20.3±5.9 mmHg, p<0.0001) and transaortic velocity (4.5±0.4 vs 2.2±0.4 m/s, p<0.0001) improved substantially from baseline to 12 months post procedure. Four all-cause mortality cases were reported up to 12 months. Moreover, there was no other moderate/severe paravalvular leak, aortic regurgitation or need for new permanent pacemaker (PPM) up to 12-month follow-up. CONCLUSIONS: The MyVal-1 study demonstrated the primary safety and efficacy of the Myval THV with no new PPM requirement up to 12-month follow-up. However, future trials with a larger number of patients and long-term follow-up are warranted to establish the safety and efficacy of the device.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2020) studied severe symptomatic native aortic stenosis (n=30). Myval transcatheter heart valve was evaluated on Safety and efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: